Advanced Cancer Diagnostics Market Size, Share & Trends 2031

Advanced Cancer Diagnostics Market Size, Share & Trends 2031

Segments - Advanced Cancer Diagnostics Market Size by Products (Genomics Based, Epigenomics Based, Proteomics Based, and Cellular Analysis Based) and Regions (Asia Pacific, North America, Latin America, Europe and Middle East & Africa)- Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vineet
Fact-checked by : Vineet Pandey
https://growthmarketreports.com/Vishal
Editor : Vishal Golekar

Upcoming | Report ID :HC-588 | 4.6 Rating | 76 Reviews | 194 Pages | Format : PDF Excel PPT

Report Description


Advanced Cancer Diagnostics Market Outlook 2031

The global advanced cancer diagnostics market size was USD XX Billion in 2022 and is anticipated to reach USD XX Billion by 2031 register a significant CAGR XX% during the forecast period, 2023-2031. The growth of the market is attributed to the rapidly increasing occurrences of the cancer disease along with the growing of patient awareness levels.

Cancer is defined as a collection of diseases that involves abnormal cell growth which has the ability to spread and invade towards additional components of the body, unlike tumors. Initial symptoms and signs include prolonged cough, a lump, change in bowel movements, unexplained weight loss and abnormal bleeding.

Advanced Cancer Diagnostics Market Outlook

Researchers, doctors and scientists have discovered different approaches to the treatment of cancer, which varies upon the stages which the patient is undergoing. Physical examinations are the preliminary methods where the doctors will search for any abnormalities in the patient such as enlargement of certain organs and changing in skin color. Laboratory testing such as blood and urine tests helps the doctors identify deformities that can lead to cancer.

Imaging tests allow the doctor to investigate the patient’s internal organs and bones and search for signs leading to cancer. The doctors can also collect samples of cells for the biopsy testing, which depends on the organ to which the cancer is diagnosed towards. According to the reports of World Cancer Research Fund International, global cancer occurrences is expecting to rise to more than 19 million cases by 2028.


The COVID-19 pandemic has reduced the growth of the global cancer diagnostics product & services market initially. However, upon further studies, researchers and scientists found out that the coronavirus has the viral gene of accelerating illness of the hosts. Basically, a patient of cancer was more susceptible to the COVID-19 virus than that of a healthy person.

This steered to hospitals, clinics, and healthcare laboratories to focus more on both COVID-19 vaccination and cancer diagnosis simultaneously for the prevention and treatment of diseases and this led to its market growth.

Drivers

Increasing knowledge of cancer from both the doctors & the public along with Government initiatives for the treatment and diagnosis of this disease, is projected to boost the global advanced cancer diagnostics market growth during the forecast period, 2021-2028. Healthcare professionals have focused on the research and development studies about cancer, its symptoms, the different stages and how to identify each of them with respect to their patients and the best treatment program available for the same.
 

Rapid growth of funding and investments from both the Government and private investors to the diagnosis to cancer are also major factors driving the market expansion in the coming years.

Restraints

The devices and equipment used for screening practices such as imaging, endoscopy and other laboratory tests will enable the detection of disease at the preliminary stage. However, there are risk factors when following the medical imaging which includes radiation exposure to fluorescent, improper administration of Barium contrast and other endoscopic and imaging procedures.

This requires high maintenance cost for safety & execution and thereby hinders the global advanced cancer diagnostics market growth. 
Lack of adequate healthcare infrastructure, especially in the developing economies, present as main challenges that can restrict the market expansion in the coming years.

Opportunities/Trends

R&D investment and technological advancement are expected to offer significant opportunities for the market players. Researchers and scientists have now discovered advanced diagnostic techniques such as the next generation sequencing, high density microarrays, cellular analysis involving capture & identification, lab-on-a-chip, real time PCR or the RT-PCR, and multiplied assays.               

Scope of The Advanced Cancer Diagnostics Market Report

The report on the global advanced cancer diagnostics market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Advanced Cancer Diagnostics Market Size - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2022

Historic Data

2016–2021

Forecast Period

2023–2031

Segmentation

By Products (Genomics Based, Epigenomics Based, Proteomics Based and Cellular Analysis Based)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast

Key Players Covered in the Report

Roche Diagnostics; Abbott Laboratories; Biocept; Beckman Coulter Inc; Becton Dickinson and Co.; Affymetrix Inc; Biotheranostics; GE Healthcare; Gen-Probe Inc; and Others

Global Advanced Cancer Diagnostics Market Segment Insights

The genomics based segment is projected to represent a large market share

Based on the products available, the global advanced cancer diagnostics market is divided into genomics based, epigenomics based, proteomics based, and cellular analysis based. The genomics based segment is expected to constitute a major share of the market during the forecast years, 2023-2031 owing to the technological advancements such as the enhanced protein-coding, high resolution genome wide screening and super genome sequencing.

These techniques have not only discovered latest cancer threats and causes, but also improved upon the existing methods in terms of efficiency and efficacy.

Advanced Cancer Diagnostics Market Products

North America is anticipated to dominate the global advanced cancer diagnostics market

On the basis of regions, the global advanced cancer diagnostics market is categorized as Asia Pacific, North America, Latin America, Europe and Middle East & Africa. North America is expecting to expand at an impressive and healthy CAGR during the forecast period, 2023-2031.

This regional market growth can be attributed to the existence of high patient awareness which encourages patients to undergo diagnostic procedures along with the healthcare infrastructure available for people from this region.

Advanced Cancer Diagnostics Market Region

Segments


The global advanced cancer diagnostics market size has been segmented in terms of

Products

  • Genomics Based
  • Epigenomics Based
  • Proteomics Based
  • Cellular Analysis Based

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Roche Diagnostics
  • Abbott Laboratories
  • Biocept
  • Beckman Coulter Inc
  • Becton Dickinson and Co.
  • Affymetrix Inc
  • Biotheranostics
  • GE Healthcare
  • Gen-Probe Inc
  • Others

Competitive Landscape

Major players competing in the global advanced cancer diagnostics market are Roche Diagnostics; Abbott Laboratories; Biocept; Beckman Coulter Inc; Becton Dickinson and Co.; Affymetrix Inc; Biotheranostics; GE Healthcare; Gen-Probe Inc; and others. These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.

They are simultaneously looking to innovate the current product they have in order to get a competitive edge in the market. For instance, in January 2020, Roche Diagnostics developed the interventional radiology that involves the usage of invasive techniques such as catheters and needles which also provides alternative surgery to some patients.

Advanced Cancer Diagnostics Market Key Players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Advanced Cancer Diagnostics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Advanced Cancer Diagnostics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Advanced Cancer Diagnostics Market - Supply Chain
  4.5. Global Advanced Cancer Diagnostics Market Forecast
     4.5.1. Advanced Cancer Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Advanced Cancer Diagnostics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Advanced Cancer Diagnostics Market Absolute $ Opportunity
5. Global Advanced Cancer Diagnostics Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Advanced Cancer Diagnostics Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Advanced Cancer Diagnostics Demand Share Forecast, 2019-2026
6. North America Advanced Cancer Diagnostics Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Advanced Cancer Diagnostics Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Advanced Cancer Diagnostics Demand Share Forecast, 2019-2026
7. Latin America Advanced Cancer Diagnostics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Advanced Cancer Diagnostics Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Advanced Cancer Diagnostics Demand Share Forecast, 2019-2026
8. Europe Advanced Cancer Diagnostics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Advanced Cancer Diagnostics Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Advanced Cancer Diagnostics Demand Share Forecast, 2019-2026
9. Asia Pacific Advanced Cancer Diagnostics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Advanced Cancer Diagnostics Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Advanced Cancer Diagnostics Demand Share Forecast, 2019-2026
10. Middle East & Africa Advanced Cancer Diagnostics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Advanced Cancer Diagnostics Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Advanced Cancer Diagnostics Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Advanced Cancer Diagnostics Market: Market Share Analysis
  11.2. Advanced Cancer Diagnostics Distributors and Customers
  11.3. Advanced Cancer Diagnostics Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Roche Diagnostics
     11.4.2. Abbott Laboratories
     11.4.3. Biocept
     11.4.4. Beckman Coulter Inc
     11.4.5. Becton Dickinson and Co.

Methodology

Our Clients

Microsoft
Deloitte
The John Holland Group
Honda Motor Co. Ltd.
Dassault Aviation
Siemens Healthcare
Nestle SA
sinopec